Mineralys Therapeutics Inc. Common Stock (MLYS) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 31.50
(+175.59%)
Based on the Mineralys Therapeutics Inc. Common Stock stock forecast from 2 analysts, the average analyst target price for Mineralys Therapeutics Inc. Common Stock is USD 31.50 over the next 12 months. Mineralys Therapeutics Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Mineralys Therapeutics Inc. Common Stock is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Mineralys Therapeutics Inc. Common Stock’s stock price was USD 11.43. Mineralys Therapeutics Inc. Common Stock’s stock price has changed by -5.30% over the past week, -10.98% over the past month and -19.68% over the last year.
No recent analyst target price found for Mineralys Therapeutics Inc. Common Stock
No recent average analyst rating found for Mineralys Therapeutics Inc. Common Stock
Company Overview Mineralys Therapeutics Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Read Less
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone sy...Read More
Frequently Asked Questions About Mineralys Therapeutics Inc. Common Stock (MLYS) Stock
Based on ratings from 2 analysts Mineralys Therapeutics Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on MLYS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for MLYS is USD 31.50 over the next 12 months. The maximum analyst target price is USD 33 while the minimum anlayst target price is USD 30.
Unfortunately we do not have enough data on MLYS's stock to indicate if its overvalued.
The last closing price of MLYS's stock was USD 11.43.
The most recent market capitalization for MLYS is USD 0.56B.
Based on targets from 2 analysts, the average taret price for MLYS is projected at USD 31.50 over the next 12 months.
This means that MLYS's stock price may go up by +175.59% over the next 12 months.
We can't find any ETFs which contains Mineralys Therapeutics Inc. Common Stock's stock.
As per our most recent records Mineralys Therapeutics Inc. Common Stock has 28 Employees.
Mineralys Therapeutics Inc. Common Stock's registered address is 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087.
You can get more information about it from Mineralys Therapeutics Inc. Common Stock's website at https://mineralystx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MLYS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
